(Q42984893)

12 November 2017

title

Optimized threshold for serum HCV RNA to predict treatment outcomes in hepatitis C patients receiving peginterferon alfa-2a/ribavirin (English)

1 reference

12 November 2017

1 reference

6

1 reference

12 November 2017

3

K Rajender Reddy

1 reference

12 November 2017

S Zeuzem

1

1 reference

12 November 2017

M Rodríguez-Torres

2

1 reference

12 November 2017

P Marcellin

4

1 reference

12 November 2017

M Diago

5

1 reference

12 November 2017

P Pockros

7

1 reference

12 November 2017

M Rizzetto

8

1 reference

12 November 2017

D Bernstein

9

1 reference

12 November 2017

M L Shiffman

10

1 reference

12 November 2017

A Lin

11

1 reference

12 November 2017

F Tatsch

12

1 reference

12 November 2017

S Hadziyannis

13

1 reference

12 November 2017

publication date

14 May 2012

1 reference

Journal of Viral Hepatitis

12 November 2017

published in

1 reference

12 November 2017

volume

19

1 reference

12 November 2017

issue

11

1 reference

12 November 2017

page(s)

766-774

1 reference

American Gastroenterological Association technical review on the management of hepatitis C.

12 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01624.X

Diagnosis, management, and treatment of hepatitis C: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01624.X

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01624.X

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01624.X

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01624.X

Efficacy and safety of two-dose regimens of peginterferon alpha-2a compared with interferon alpha-2a in chronic hepatitis C: a multicenter, randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01624.X

Peginterferon alfa-2a in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01624.X

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01624.X

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01624.X

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01624.X

Molecular diagnostics of hepatitis C virus infection: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01624.X

Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01624.X

Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01624.X

Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01624.X

Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01624.X

Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01624.X

Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01624.X

Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01624.X

National institutes of health consensus development conference statement: Management of hepatitis C: 2002 — June 10–12, 2002

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01624.X

Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01624.X

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01624.X

Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01624.X

10.1111/J.1365-2893.2012.01624.X

21 January 2018

Identifiers

DOI

1 reference

12 November 2017

1 reference